Adage Capital Partners
MYGN icon

Adage Capital Partners’s Myriad Genetics MYGN Stock Holding History

Adage Capital Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-150,000
Closed -$4.57M – 1047
2021
Q1 		$4.57M Sell
150,000
-41,310
-22% -$1.17M 0.01% 809
2020
Q4 		$3.78M Buy
+191,310
New +$3.09M 0.01% 711
2013
Q3 		– Sell
-600,000
Closed -$16.1M – 717
2013
Q2 		$16.1M Buy
+600,000
New +$17.4M 0.05% 412

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Adage Capital Partners's MYGN Position: Q2 2021 in Review

Adage Capital Partners sold out of Myriad Genetics (MYGN) in Q2 2021, closing a stake of 150,000 shares — an estimated $4.57M sold.

Adage Capital Partners first reported a position in MYGN in Q2 2013 and held it in 3 quarters. The position peaked at $16.1M in Q2 2013. 201 funds tracked by Wall St. Rank hold MYGN as of Q2 2021.

  • Adage Capital Partners reported no remaining Myriad Genetics position as of Q2 2021 after selling out during the quarter.
  • Adage Capital Partners sold 150,000 Myriad Genetics shares in Q2 2021, an estimated $4.57M.
  • Adage Capital Partners first reported a position in Myriad Genetics in Q2 2013 and held it in 3 quarters.
  • Adage Capital Partners's Myriad Genetics position peaked at $16.1M in Q2 2013.
  • 201 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2021.

Based on Adage Capital Partners's 13F filing for Q2 2021, filed 16 Aug 2021.